RIFERIMENTI BIBLIOGRAFICI
Ackley C.D., Hoover E.A., Cooper M.D. (1990). Identification of CD4 homologue
in the cat. Tissue Antigens. 35(2): 92-8.
Akkina R.K., Walton R.M., Chen M.L., Li Q.X., Planelles V., Chen I.S. (1996).
High-efficiency gene transfer into CD134+ cells with human immunodeficiency virus type 1-based retroviral vector pseudotyped with vescicular stomatitis virus envelope glycoprotein G. J. Virol. 70: 2581-2585.
Al Shamkhani A., Birkeland M.L., Puklavec M., Brown M.H., James W., Barclay A.N. (1996). OX40 is differentially expressed on activated rat and mouse T cells
and is the sole receptor for the OX40 ligand. Eur. J. Immunol. 26: 1695-1699.
Amara R.R., Villinger F., Altman J.D., Lydy S.L., O’Neill S.P., Staprans S.I., Montefiori D.C., Xu Y., Herndon J.G., Wyatt L.S., Candido M.A., Kozyr N.L., Earl P.L., Smith J.M., Ma H.L., Grimm B.D., Hulsey M.L., Miller J., McClure H.M., McNicholl J.M., Moss B., Robinson H.L. (2001). Control of mucosal
challenge and prevention of AIDS by a multiprotein DNA/MVA vaccine. Science
292: 69-74.
Amara R.R., Smith J.M., Staprans S.I., Montefiori D.C., Villinger F., Altman J.D., O’Neill S.P., Kozyr N.L., Xu Y., Wyatt L.S., Earl P.L., Herndon J.G., McNicholl J.M., McClure H.M., Moss B., Robinson H.L. (2002). Critical role for
Env as well as Gag-Pol in control of a Simian-Human immunodeficiency virus 89.6P challenge by a DNA prime/recombinant modified vaccinia virus Ankara vaccine. J. Virol. 76: 6138-6146.
Bandecchi P., Matteucci D., Baldinotti F., Guidi G., Abramo F., Tozzini F., Bendinelli M. (1992). Prevalence of feline immunodeficienty virus and other
retroviral infections in sick cats in Italy. Vet. Immunol. Immunopatol. 31: 337-345.
Barouch D.H., Craiu A., Kuroda M.J., Schmitz J.E., Zheng X.X., Santra S., Frost J.D., Krivulka G.R., Lifton M.A., Crabbs C.L., Heidecker G., Perry H.C., Davies M E., Xie H.,et al. (2000). Augmentation of immune responses to HIV-1
and simian immunodeficiency virus DNA vaccines by IL-2/Ig plasmid administration in rhesus monckeys. Proc. Natl. Acad. Sci. USA 97: 4192-4197.
Barouch D.H., Letvin N.L. (2000). DNA vaccination for HIV-1 and SIV.
Intervirology 43: 282-287.
Barouch D.H., Santra S., Tenner-Racz K., Racz P., Kuroda M.J., Schmitz J.E., Jackson S.S., Lifton M.A., Freed D.C., Perry H.C., Davies M.E., Shiver J.W., Letvin N.L. (2002). Potent CD4+ T cell responses elicited by a bicistronic
Barouch D.H., McKay P.F., Sumida S.M., Santra S., Jackson S.S., Gorgone D.A., Lifton M.A., Chakrubarti B.K., Xu L., Nabel G.J., Letvin N.L. (2003).
Plasmid chemokines and colony stimulating factors enhance the immunogenicity of DNA priming-viral vector boosting human immunodeficiency virus type 1 vaccines. J. Virol. 77: 8729-8735.
Beatty J.A., Willett B.J., Gault E.A., Jarrett O. (1996). A longitudinal study
of feline immunodeficiency virus-specific cytotoxic T lymphocytes in experimentally infected cats, using antigen-specific induction. J. Virol. 70: 6199-6206.
Beaumont T., van Nuenen A., Broersen S., Blattner W.A., Lukashov V.V., Schuitemaker H. (2001). Reversal of human immunodeficiency virus type 1 IIIB to
a neutralization-resistant phenotype in an accidentally infected laboratory worker with a progressive clinical course. J. Virol. 75: 2246-2252.
Beebe A.M., Dua N., Faith T.G., Moore P.F., Pedersen N.C., Dandekar S. (1994). Primary stage of feline immunodeficiency virus infection: viral dissemination
and cellular targets. J. Virol. 68: 3080-3091.
Bendinelli M., Pistello M., Lombardi S., Poli A., Garzelli C., Matteucci D., Ceccherini Nelli L., Malvali G., Tozzini F. (1995). Feline immunodeficiency virus:
an interesting model for AIDS studies and an important cat pathogen. Cl. Microb. Rev. 8: 87-112.
Bendinelli M., Pistello M.,Del Mauro D., Cammarota G., Maggi F., Leonildi A., Giannecchini S., Bergamini C., Matteucci D. (2001). Durino readaptetion in vivo, a
tissue culture-adapted strain of feline immunodeficiency virus reverts to broad neutralization resistence at different times in individual hosts but through changes at the same position of the surface glycoprotein. J. Virol. 75: 4584-4593.
Bennet M., Hart C.A. (1995). Feline immunodeficiency virus infection- a model for
HIV and AIDS ?. J. Med. Microbiology 42: 233-236.
Berger E.A., Murphy P.M., Farber J.M. (1999). Chemokine receptors as HIV-1
coreceptors: roles in viral entry, tropism, and disease. Ann. Rev. Immunol. 17: 657-700.
Blomer U., Naldini L., Kafri T., Trono D., Verma I.M., Gage F.H. (1997).
Highly efficient and sustained gene transfer in adult neurons with a lentivirus vector. J. Virol. 71: 6641-6649.
Borrello I, Pardoll D. (2002). GM-CSF-based cellular vaccines: a review of the
clinical experience. Cytokine Growth Factor Rev. 13: 185-193.
Borrow P., Lewicki H., Hahn B.H., Shaw G.M., Oldstone M.B. (1994). Virus
specific CD8+ cytotoxic T-lymphocyte activity associated with control of viremia in primary human immunodeficiency virus type 1 infection. J. Virol. 68: 6103-6110.
Bowne W.B., Wolchok J.D., Hawkins W.G., et al. (1999). Injection of DNA
ancoding granulocyte-macrophage colony-stimulating factor recruits dendric cells for immune adjuvant effects. Cytochine cell. Mol. Ther. 5(4): 217-225.
Boyer J.D., Kim J., Ugen K.E., Cohen A.D., Ahn L., Schumann K., Lacy K., Bagarazzi M.L., Javadian A., Ciccarelli R., Ginsberg R.S., Mac Gregor R.R., Weiner D.B. (1999). HIV-1 DNA vaccines and chemokines. Vaccine 17: (suppl) 53-64.
Burkard M.J., Dean G.A. (2003). Trasmission and immunopathogenesis of feline
immunodeficiency virus in cats as a model for HIV. Curr. HIV Res. 12: 1258-1264.
Callanan J.J., Hosie M.J., Jarrett O. (1991). Transmission of feline
immunodeficiency virus from mother to kitten. Vet. Rec. 128: 332-333.
Caputo A., Betti M., Boarini C., Mantovani I., Corallini A., Barbanti-Brodano G. (1999). Multiple functions of human immunodeficiency virus type 1 Tat protein in
the pathogenesis of AIDS. Rec. Res. Devel. Virol. 1: 753-771.
Chatterji U., De Parseval A.P., Elder J.H. (2002). Feline immunodeficiency virus
Orf-A is distinct from the other lentivirus transactivators. J. Virol. 76: 9624-9634.
Chinnasamy D., Chinnasamy M., Enriquez M.J., Otsu M., Morgan R.A., Candotti F. (2000). Lentiviral-mediated gene transfer into human lymphocytes: role
of HIV-1 accessory protein. Blood 96: 1309-1316.
Chong H., Starkey W., Vile R.G. (1994). A replication-competent retrovirus
arising from a split-function packaging cell line was generated by recombination events between the vector, one of the packaging constructs and endogenous retroviral sequences. J. Virol. 72: 2663-2670.
Curran M.A., Kaiser S.M., Achacoso P.L., Nolan G.P. (2000). Efficient
transduction of nondividing cells by optimized feline immunodeficiency virus vectors. Mol. Ther. 1: 31-38.
Dean G.A., Reubel G.H., Moore P.F., Pedersen N.C. (1996). Proviral
burden and infection kinetics of feline immunodeficiency virus in lymphocyte subsets of blood and lymph node. J. Virol. 70: 5165-5169
.
De Parseval A.P., Elder J.H. (1999). Demostration that Orf2 encodes the feline immunodeficiency virus transactivating (Tat) protein and characterization of a unique gene product with partial rev activity. J. Virol. 73: 608-617.
De Parseval A., Chatterji U., Sun P., Elder J.H. (2004). Feline
immunodeficiency virus targets activated CD4+ T cells by using CD134 as a binding receptors. Proc. Natl. Acad. Sc. USA 12: 1435-1440
Doria-Rose N.A., Haigwood N.L. (2003) DNA vaccines strategies: candidates for
Dua N., Reubel G., Higgins J., Moore P.F., Pedersen N.C. (1994). An
experimental study of primary feline immunodeficiency virus infection in cats and a historical comparison to acute simian and human immunodeficiency virus disease. Vet. Immunol. Immunopathol. 43: 337-355.
Durkop H., Latza U., Himmelreich P., Stein H. (1995). Expression of the human
OX40 (hOX40) antigen in normal and neoplastic tissue. Br. J. Haematol. 91(4):927-31.
Elder J.H., Phillips T.R. (1994). Molecular properties of feline immunodeficiency
virus (FIV). Inf. Agent Dis. 2: 361-374.
Elder J.H., Phillips T.R. (1995). Feline immunodeficiency virus as a model for
development of molecular approaches to intervention strategies against lentivirus infections. Adv. Vir. Reser. 45: 225-247.
English R.V., Johnson C.V., Gebhard D.H., Tompkins R.B. (1993). In vivo
lymphocyte tropism of feline immunodeficiency virus. J. Virol. 67: 5175-5186.
Felber B.K., Hadzopoulou-Cladaras M., Cladaras C., Copeland T., Pavlakis G.N. (1989). Rev protein of human immunodeficiency virus type 1 affects the stability
and transport of the viral RNA. Proc. Nat.Acad.Sc. USA 86: 1495-1499.
Flynn J.N., Cannon C.A., Reid G., Rigby M.A., Neil J.C., Jarrett O. (1995).
Induction of feline immunodeficiency virus-specific cell-mediated and humoral immune responses following immunization with a multiple antigenic peptide from the envelope V3 domain. Immunology 85: 171-175.
Flynn J.N., Keating P., Hosie M.J., Mackett M., Stephens E.B., Beatty J.A., Neil J.C., Jarrett O. (1996). Env-specific CTL predominate in cats protected
from feline immunodeficiency infection by vaccination. J. Immunol. 157: 3658-3665.
Flynn N.J., Hosie M.J., Rigby M.A., Mackay N., Cannon C.A., Dunsford T., Neil J.C., Jarrett O. (2000). Factors influencing cellular immune responses to
feline immunodeficiency virus induced by DNA vaccination. Vaccine 18: 1118-1132.
Friedmann T., Yee J.K. (1995). Pseudotyped retroviral vectors for studies of
human gene therapy. Nat. Med. 1: 275-277.
Gaskell R.M., Bennett M. (1996). Feline and canine infectious diseases (Sutton,
J.B., Ed.), Blackwell Science, Cambridge.
Gemeniano M.C., Sawai E.T., Leutenegger C.M., Sparger E.E. (2003). Feline
immunodeficiency virus ORF-A is required for virus particle formation and virus infectivity. J. Virol. 77: 8819-8830.
Gemeniano M.C., Sawai E.T., Sparger E.E. (2004). Feline immunodeficiency virus
Giannecchini S., Del Mauro D., Matteucci D., Bendinelli M. (2001). AIDS
vaccination studies using an ex vivo feline immunodeficiency virus model: reevaluation of neutralizing antibody levels elicited by a protective and a nonprotective vaccine after removal of antisubstrate cell antibodies. J. Virol. 75: 4424-4429.
Goldman M.J., Lee P.S., Yang J.S., Wilson J.M. (1997). Lentiviral vector for
gene therapy of cystic fibrosis. Hum. Gene Ther. 8: 2261-2268.
Gonin P., Fournier A., Oualikene W., Moraillon A., Eloit M. (1995).
Immunization trial of cats with a replication defective adenovirus type 5 expressing the Env gene of feline immunodeficiency virus. Vet. Microbiol. 45:393-401.
Gurunathan S., Klinman D.M. Seder R.A. (2000). DNA vaccines: immunology,
application and optimization. Ann. Rev. of Immunol. 18: 927-974.
Haddad D., Ramprakash J., Sedegah M., Charoenvit Y., Baumgartner R., Kumar S., Hoffman S.L., Weiss W.R. (2000). Plasmide vaccine expressing
granulocyte-macrophage colony-stimulating factor attracts infiltrates including immature dendritic cells into injected muscles. J. Immunol. 165: 3772-3781.
Hanke T., Samuel R.V., Blanchard T.J., Neumann V.C., Allen T.M., Boyson J.E., Sharpe S.A., Cook N., Smith G.L., Watkins D.I., Cranage M.P., McMichael A.J. (1999). Effective induction of simian immunodeficiency
virus-specific cytotoxic T lymphocytes in macaques by using a multiepitope gene and DNA prime-modified vaccinia virus Ankara boost vaccination regimen. J Virol. 73: 7524-7532.
Harbour D.A. (1992). Feline immunodeficiency virus infection as a model for HIV
infection in man. Rev. Med. Virol. 2: 43-49.
Hosie M.J., Robertson M.C., Jarrett O. (1989). Prevalence of feline leukaemia
virus and antibody to feline immunodeficienty virus in cats in United Kingdom. Vet. Rec. 128: 293-297.
Hosie M.J., Osborne R., Reid G., Neil J.C., Jarrett O. (1992). Enhancement
after feline immunodeficiency virus vaccination. Vet. Immunol. Immunopathol. 35: 191-197.
Hosie M.J., Flynn J.N., Rigby M.A., Cannon C., Dunsford T., Mackay N.A., Argyle D., Willet B.J., Miyazawa T., Onions D.E., Jarrett O., Neil J.C. (1998). DNA vaccination affords significant protection against feline
immodeficiency virus infection without inducing detectable antiviral antibody. J. Virol. 72: 7310-7319.
Ikeda Y., Tomonaga K., Kawaguchi Y., Kohmoto M., Inoshima Y., Tohya Y., Miyazawa T., Kai C., Mikami T. (1996). Feline immunodeficiency virus can infect
a human cell line (MOLT-4) but establishes a state of latency in the cells. J. Gen.Virol. 77: 1623-1630.
Ishida e Tomoda (1990). Clinical staging of feline immunodeficiency virus infection.
Jpn. J. Vet. Sci. 52: 645-648.
Jarrett O., Yamamoto J.K., Neil J.C. (1990). Feline immunodeficiency virus as a
model for AIDS vaccination. AIDS, 4, (Suppl. 1), S163-165.
Johnson C.M., Torres B.A., Koyama H., Yamamoto J.K. (1994). Tenth
Anniversary Perspectives on AIDS: FIV as a model for AIDS vaccination. AIDS Res. Hum. Retroviruses. 10: 225-228.
Johnston J.C., Gasmi M., Lim L.E., Elder J.H., Yee J.K., Jolly D.J., Campbell K.P., Davidson B.L., Sauter S.L. (1999). Minimum requirements for efficient
transduction of dividing and nondividing cells by feline immunodeficiency virus vectors. J. Virol. 73: 4991-5000.
Kafri T., Blomer U., Peterson D.A., Gage F.H., Verma I.M. (1997). Sustained
expression of genes delivered directly into liver and muscle by lentiviral vectors. Nat. Genet. 17: 314-317.
Kang Y., Stein C.S., Heth J.A., Sinn P.L., Penisten A.K., Staber P.D., Ratliff K.L. Shen H., Barker C.K., Martins I., Sharkey C.M., Sanders D.A., McCray P.B. Jr., Davidson B.L. (2002). In vivo gene transfer using nonprimate lentiviral vector pseudotyped with Ross River Virus glycoproteins. J. Virol. 76: 9378-9388.
Kemler I., Barraza R., Poeschla E.M. (2002). Mapping the encapsidation
determinants of feline immunodeficiency virus. J. Virol. 76: 11889-11903.
Kim J.J., Yang J.S., Lee D.J., et al. (2000). Macrophage colony stimulating
factor can modulate immune response and attract dendritic cells in vivo. Hum. Gene Ther. 11(2): 305-321.
Kirkanides S., Miller J.H., Federoff H.J. (2003). Systemic FIV vector
administration: transduction of CNS immune cells and purkinjie neurons. Brain Res. Mol. Brain Res. 119(1): 1-9.
Kusakabe K., Xin K., Katoh H., Sumino K., Hagiwara E., Kawamoto S., Okuda K., Miyagi Y., Aoki I., Nishioka K., Klinman D., Okuda K. (2000). The timing of
GM-CSF expression plasmid administration influences the Th1/Th2 response induced by an HIV-1 specific DNA vaccine. J. Immunol. 164(6): 3102-3111.
Leitner W.W., Han Y., Nicholas P.R. (2000). DNA and RNA based vaccines:
principles, progress and prospects. Vaccine 18: 765-777
.
Letvin N.L., Huang Y., Chakrabarti B.K., Xu L., Seaman M.S., Beaudry K., Korioth-Schmitz B., Yu F., Rohne D., Martin K.L., Miura A., Kong W., Yang Z., Gelman R.S., Golubeva O. G., Montefiori D.C., Mascola J.R., Nabel G. (2004). Heterologous envelope immunogens contribute to AIDS vaccine protection
Leutenegger C.M., Borretti F.S., Mislin C.N., Flynn N.J., Schroff M., Habel A., Junghans C., Koening-Merediz S.A., Sigrist B., Aubert A., Pedersen N.C., Witting B., Lutz H. (2000). Immunization of cats against feline immunodeficiency
virus (FIV) infection by using minimalistic immunogenic defined gene expression vector vaccines expressing FIV gp140 alone or with feline interleukin-12 (12), IL-16, or a CpG motif. J. Virol. 74: 10447-10457.
Lin Y.L., Noel D., Mettling C., Réant B., Clot J., Jorgensen C., Corbeau P. (2004). Feline immunodeficiency virus vectors for efficient transduction of primary
human synoviocytes: application to an original model of rheumatoid arthritis. Hum. Gene Ther. 15: 588-596.
Liu M.L., Winther B.L., Kay M.A. (1996). Pseudotransduction of hepatocytes by
using concentrated pseudotyped vescicular stomatitis G glycoprotein (VSV-G)-Moloney murine leukaemia virus-derived retrovirus vector: comparison of VSV-G and amphotropic vectors for hepatic gene transfer. J. Virol. 70: 2497-2502.
Lombardi S., Garzelli C., Pistello M., Massi C., Matteucci D., Baldinotti F., Cammarota G., Da Prato L., Bandecchi P., Zozzini F., et al. (1994). A
neutralizing antibody-inducing peptide of the V3 domain of feline immunodeficiency virus envelope glycoprotein does not induce protective immunity. J. Virol. 68: 8374-8379.
Lu X., Humeau L., Slepushkin V., Binder G., Yu O., Slepushkina T., Chen Z., Merling R., Davis B., Chang Y.N., Dropulic B. (2004). Safe two-plasmid
production for the first clinical lentivirus vector that achieves > 99% transduction in primary cells using a one-step protocol. J. Gene Med. 6: 963-973.
Lutz H., Isenbugel E., Lehmann K., Sabapara R.H., Wolfensberger C. (1992).
Retrovirus infections in non domestic felids: serological studies and attempts to isolate a lentivirus. Vet. Immunol. Immunopat. 35: 215-224.
Matteucci D., Baldinotti F., Mazzetti P., Pistello M., Bandecchi R., Ghilarducci R., Poli A., Tozzini F., Bendinelli M. (1993). Detection of feline
immunodeficiency virus in saliva and plasma by cultivation and polymerase chain reaction. J. Clin. Microb. 3: 494-501.
Matteucci D., Pistello M., Mazzetti P., Giannecchini S., Del Mauro D., Zaccaro L., Bandecchi P., Tozzini F., Bendinelli M. (1996). Vaccination protects against
in vivo-grown feline immunodeficiency virus even in the absence of detectable neutralizing antibody. J. Virol. 70: 617-622.
Matteucci D., Pistello M., Mazzetti P., Giannecchini S., Del Mauro D., Lonetti I., Zaccaro L., Pollera C., Specter S., Bendinelli M. (1997). Studies of AIDS
vaccination using an ex vivo feline immunodeficiency virus model: protection conferred by a fixed cell vaccine against cell free and cell associated challenge differs in duration and is not easily boosted. J. Virol. 71: 8368-8376.
Matteucci D., Poli A., Mazzetti P., Sozzi S., Bonci F., Isola P., Zaccaro L., Giannecchini S., Calandrella M., Pistello M., Specter S., Bendinelli M. (2000).
Immunogenicity of anti-clade B feline immunodeficiency fixed-cell virus vaccine in field cats. J. Virol. 74: 10911-10919.
Miller A.D. (2000). Retroviruses, eds. Coffin, J., Hughes, S.H. and Varmus, H.E., Cold Spring Harbor Laboratory Press, Planview
.
Miyazawa T., Tomonaga K., Kawaguchi Y., Mikami T. (1993). The genome of
feline immunodeficiency virus. Arch. Virol. 134: 221-234.
Miyazawa T., Kawaguchi Y., Kohmoto M., Tomonaga K., Mikami T. (1994).
Comparative functional analysis of the various lentivirus long terminal repeats in human colon carcinoma cell line (SW480 cells) and feline renal cell line (CrFK cells). J. Vet. Med. Sci. 56: 895-899.
Miyoshi H., Takahashi M., Gage F.H., Verma I.M. (1997). Stable and efficient
gene transfer into the retina using an HIV-based lentiviral vector. Proc. Natl. Acad. Sci. USA 94: 10319-10323.
Moore A.C., Kong W.P., Chakrabarti B.K., and Nabel G.J. (2001). Effects of
antigen and genetic adjuvants on immune responses to human immunodeficiency virus DNA vaccines in mice. J. Virol. 76: 243-250.
Morikawa S., Bishop D.H.L. (1992). Identification and analysis of the gag-pol ribosomal frameshift site of feline immunodeficiency virus. Virology 186: 389-397.
Naldini L., Blomer U., Gallay P., Ory D., Mulligan R., Gage F.H., Verma I.M., Trono D. (1996). In vivo gene delivery and stable transduction of nondividing cells by a lentiviral vector. Science 272: 263-267.
Norimine J., Miyazawa T., Kawaguchi Y., Tomonaga K., Shin Y.S., Toyosaki T., Kohmoto M., Niikura M., Tohya Y., Mikami (1993). Feline CD4 molecule
expressed on feline non-limphoid cell lines are not enough for productive infection of highly lymphotropic feline immunodeficiency virus isolates. Arch Virol. 130(1-2): 171-8.
O’Neill E., Martinez I., Villinger F., Rivera M., Gascot S., Colon C., Arana T., Sidhu M., Stout R., Montefiori D.C., Martinez M., Ansari A.A., Israel Z.R., Kraiselburd E. (2002). Protection by SIV VLP DNA prime/protein boost following
mucosal SIV challenge is markedly enhanced by IL-12/GM-CSF co-administration. J. Med. Primatology 31: 217-227.
Pancino G., Fossati I., Chappey C., Castelot S., Hurtrel B., Moraillon A., Klatzmann D., Sonigo P. (1993). Structure and variations of feline
immunodeficiency virus envelope glycoproteins. Virology 192: 659-662.
Park E.J., Vujcic L.K., Anand R., Theodore S.T., Quinnan G.V. Jr. (1998).
resistence of variant human immunodeficiency virus type 1 MN to antibody direct at V3 and non-V3 epitopes. J. Virol. 72: 7099-7117.
Parren P.W.H.I., Moore J.P., Burton D.R., Sattentau Q.J. (1999). The
neutralization antibody response to HIV-1: viral evasion and escape from humoral immunity. AIDS 13: S137-S162.
Patrick M.K., Johnston J.B., Power C. (2002). Lentiviral neuropathogenesis:
comparative neuroinvasion, neurotropism, neurovirulence, and host neurosusceptibility. J. Virol. 76: 7923-7931.
Pedersen N.C., Ho E.W., Brown M.L., Yamamoto J.K. (1987). Isolation of a
T-lymphotropic virus from domestic cats with an immunodeficiency-like syndrome. Science 235: 790-793.
Perletti G., Osti D., Marras E., Tettamanti G., and de Eguileor M. (2004).
Generation of VSV-G pseudotyped lentiviral particles in 293T cells. J. Cell Mol. Med.
8(1): 142-143.
Phillips T.R., Lamont C., Konings D.A.M., Shacklett B.L., Hamson C.A., Luciw P.A., Elder J.H. (1992). Identification of the Rev transactivation and
Rev-responsive elements of feline immunodeficiency virus. J. Virol. 66: 5464-5471.
Pistello M., Cammarota G., Nicoletti E., Matteucci D., Curcio M., Del Mauro D., Bendinelli M. (1997). Analysis of the genetic diversity and phylogenetic
relationship of Italian isolates of feline immunodeficiency virus indicates a high prevalence and heterogeneity of subtype B. J. Virol. 78: 2247-2257.
Pistello M., Moscardini M., Mazzetti P., Bonci F., Zaccaro L., Isola P., Freer G., Specter S., Matteucci D., Bendinelli M. (2002). Development of feline
immunodeficiency virus ORF-A (tat) mutans: in vitro and in vivo characterization. Virology 298: 84-95.
Poeschla E.M., Wong-Staal F., Looney D.J. (1998). Efficient transduction of
nondividing human cells by feline immunodeficiency virus lentiviral vectors. Nat. Med.
4: 354-356.
Price M.A., Case S.S., Carbonaro D.A., Yu X.J., Petersen D., Sabo K.M., Curran M.A., Engel B.C., Margarian H., Abkowitz J.L., Nolan P.G., Kohn D.B., Crooks G.M. (2002). Expression from second-generation feline immunodeficiency
virus vector is impaired in human hematopoietic cells. Mol. Ther. 6: 645-652.
Pu R., Coleman J., Omori M., Mison M., Huang C., Arai M., Tanabe T., Yamamoto J.K. (2001). Dual subtype FIV vaccine protects cats against in vivo
swarms of both homologous and heterologous sbtype FIV isolates. AIDS 15: 1-13.
Richardson J., Pancino G., Merat R., Leste-Laresse T., Moraillon A., Schneider-Mergene R., Alizon M., Sonigo P., Heveker N. (1999). Shared usage
of the chemokine receptor CXCR4 by primary and laboratory-adapted strains of feline immunodeficiency virus
.
J. Virol. 73(5):3661-71.Rinaldo C., Huang X.L., Fan Z.F., Ding M., Beltz L., Logar A., Panicali D., Mazzara G., Liebmann J., Cotrill M, et al. (1995). High levels of anti-human
immunodeficiency virus type 1 (HIV-1) memory citotoxic T-lymphocyte activity and low viral load are associated with lack of disease in HIV-1 infected long-term nonprogressor. J. Virol. 69: 5838-5842.
Shimojima M., Miyazawa T., Ikeda Y., McMonagle E.L., Haining H., Akashi H., Takeuchi Y., Hosie M.J., Willett B.J. (2004). Use of CD134 as a primary
receptor by the feline immunodeficiency virus. Science 303: 1192-1195.
Siebelink K.H.J., Chu I.H., Rimmelzwaan G.F., Weijer K., Van Herwijner R., Knell P., Egberink H.F., Bosch M.L., Osterhaus A.D.M.E. (1990). Feline
immunodeficiency virus (FIV) infection in the cat as a model for HIV infection in man: FIV-induced impairment of immune function. AIDS Res. Hum. Retroviruses 6: 1373-1378.
Sparger E.E., Shacklett B.L., Renshaw-Gegg L., Barry P.A., Pedersen N.C., Elder J.H., Luciw P.A. (1992). Regulation of gene expression directed by the long terminal repeat of the feline immunodeficiency virus. Virology 187: 165-177.
Song J.J., Lee B., Chang J.W., Kim J.H., Kwon Y.K., Lee H. (2003).
Optimization of vescicular stomatitis virus-G pseudotyped feline immunodeficiency virus vector for minimized cytotoxicity with efficient gene transfer. Virus Research
93: 25-30.
Sun X., Hodge LM, Jones HP, Tabor L, Simecka JW. (2001) Co-expression of
granulocyte-macrophage colony-stimulating factor with antigen enhances humoral and tumor immunity after DNA vaccination. Vaccine 20: 1466-1474.
Takeuchi T., Cosset F.L., Lachmann P.J., Okada H., Weiss R.A., Collins M.K. (1994). Type C retrovirus inactivation by human complement is determined by both
the viral genome and the producer cell. J. Virol. 68: 8001-8007.
Takodoro C. E., De Almeida Abrahamson I. (2001). Bone marrow-derived
macrophage grown in GM-CSF or M-CSF differ in their ability to produce IL-12 and to induce IFN-γ production after stimulation with Trypanosoma cruzi antigens. Immunol. Lett. 77(1): 31-38.
Talbott R.L., Sparger E.E., Lovelace K.M., Fitch W.M., Pedersen N.C., Luciw P.A., Elder J.H. (1989). Nucleotide sequence and genomic organization of feline immunodeficiency virus. Proc. Natl. Acad. Sci. USA 86: 5743-5747.
Tomonaga K., Miyazawa T., Kawaguchi Y., Kohmoto M., Inoshima Y., Mikami T. (1994). Comparison of the Rev transactivation of feline immunodeficiency virus in
Tomonaga K., Mikami T. (1996). Molecular biology of the feline immunodeficiency
virus auxiliary genes. J. Gen. Virol. 77: 1611-1621.
Torten M., Franchini M., Barlough J.E., George J.W., Mozes E., Lutz H., Pedersen N.C. (1991). Progressive immune dysfunction in cats experimentally
infected with feline immunodeficiency virus. J. Virol. 65: 2225-2230.
Vahlenkamp T.W., de Ronde A., Schuurman N.N., van Vliet A.L., van Drunen J., Horzinek M.C., Egberink H.F. (1999). Envelope gene sequences encoding
variable regions 3 and 4 are involved in macrophage tropism of feline immunodeficiency virus. J. Gen. Virol. 80: 2639-2646
.
Van Tendeloo V.F.I., Van Broeckhoven C., Berneman Z.N. (2001). Gene therapy:
principles and applications to hematopoietic cells. LeuKemia 15: 523-544.
Wang G., Slepushkin V., Zabner J., Keshavjee S., Johnston J.C., Sauter S.L., Jolly D.J., Dubensky T.W. Jr., Davidson B.L., McCray P.B. Jr. (1999). Feline
immunodeficiency virus vectors persistently transduce nondividing airway epithelia and correct the cystic fibrosis defect. J. Clin. Invest. 104: R55-R62.
Warren T.L., and Weiner G.J. (2000). Uses of granulocyte macrophage colony
stimulating factor in vaccine development. Curr. Opin. Hematol. 7(3): 168-173.
Waters A.K., de Parseval A.P., Lerner D.L., Neil J.C., Thompson F.J., Elder J.H. (1996). Influence of ORF2 on host cell tropism of feline immunodeficiency virus. Virology 215: 10-16.
Wei X., Decker J.M., Wang S., Hui H., Kappes J.C., Wu X., Salazar-Gonzales J.F., Salazar M.G., Kilby J.M., Saag M.S., Komarova N.L., Nowak M.A., Hahn B.H., Kwong P.D., Shaw G.M. (2003). Antibody neutralization and
escape by HIV-1. Nature 422: 307-312.
Whitwam T., Peretz M., Poeschla E. (2001) Identification of a central DNA flap
in feline immunodeficiency virus. J.Virol. 75: 9407-9414.
Willet B.J., Hosie M.J., Dunsford T.H., Neil J.C., Jarrett O. (1991).
Productive infection of T-helper lymphocytes with feline immunodeficiency virus is accompanied by reduced expression of CD4. AIDS 5:1469-1475.
Willett B.J., Flynn J.N., Hosie M.J. (1997).
FIV infection of the domestic cat:
an animal model for AIDS. Immunol. Today 18: 182-189.
Willett B.J., Cannon C.A., Hosie M.J. (2002). Upregulation of surface feline
CXCR4 expression following ectopic expression of CCR5: implications for studies of the cell tropism of feline immunodeficiency virus. J. Virol. 76(18):9242-52.
Woodland D.L. (2004) Jump-starting the immune system: prime-boosting comes of
Yamamoto, J.K., Okuda, T., Ackley, C.D., Louie, H., Pembroke, E., Zochlinski, H., Munn, R.J., Gardner M.B. (1990). Experimental vaccine protection against
feline immunodeficiency virus. AIDS Res. Hum. Retroviruses 7: 911-922.
Yamamoto, J.K., Hohdatsu T., Olmsted R.A., Pu R., Louie H., Zochlinski, H., Acevedo V., Johnson H.M., Soulds G.A., Gardner M.B. (1993). Experimental
vaccine protection against homologous and heterologous strains of feline immunodeficiency virus. J. Virol. 67: 601-605.
Zarei S., Abraham S., Arrighi J.F., Haller O., Calzascia T., Walker P.R., Kundig T.M., Hauser C., Piguet V. (2004). Lentiviral trasdution of dendritic cells
confert protective antiviral immunity in vivo. J.Virol 78: 7843-7845.
Zennou V., Petit C., Guetard D., Nerhbass U., Montagnier L., Charneau P. (2000) HIV-1 genome nuclear import is mediated by a central DNA flap. Cell 101: 173-185.
